Publications

Atayee RS, Best BM, Daniels CE. Development of an ambulatory palliative care pharmacist practice. Journal of Palliative Medicine, 11:1077-1082, 2008.

Atkinson JH, Slater MA, Capparelli EV, Wallace MS, Zisook S, Abramson I, Matthews SC, Garfin SR. Efficacy of noradrenergic and serotonergic antidepressants in chronic back pain: a preliminary concentration-controlled trial. J Clin Psychopharmacol,  27(2):135-42, 2007.

Bayele HK, Peyssonnaux C, Giatromanolaki A, Arrais-Silva WW, Mohamed HS, Collins H, Giorgio S, Koukourakis M, Johnson RS, Blackwell JM, Nizet V, Sria SK. HIF-1a regulates heritable variation and allele expression phenotypes of the macrophage immune response gene SLC11A1 from a Z DNA forming microsatellite. Blood, 110:3039-3048, 2007.

Best B, Capparelli EV.  Implications of gender and pregnancy for antiretroviral drug dosing. Cur Opinion HIV and AIDS, 3:277-282, 2008.

Best BM, Goicoechea M. Efavirenz - still first-line king? Expert Opinion on Drug Metabolism and Toxicology, 4:965-72, 2008.

Borkowsky W, Yogev R, Muresan P, McFarland E, Frenkel L, Fenton T, Capparelli EV, Moye J, Harding P, Ellis N, Heckman B, Kraimer J. Planned multiple exposures to autologous virus in HIV-1 infected pediatric populations increases HIV-specific immunity and reduces HIV viremia. J Acquire Immuno Def Synd, 24:401-11, 2008.

Borkowsky W, Yogev R, Muresan P, McFarland E, Frenkel L, Fenton T, Capparelli EV, Moye J, Harding P, Ellis N, Heckman B, Kraimer J. Structured treatment interruptions (STIs) in HIV-1 infected pediatric populations increases interferon gamma production and reduces viremia. Vaccine, 26:3086-9, 2008.

Bradley JS, Sauberan JB, Ambrose PG, Bhavnain SM, Rasmussen MR, Capparelli EV. Meropenem pharmacokinetics, pharmacodynamics and Monte Carlo simulation in the neonate. Pediatr Infect Dis J, 2 7:794-9, 2008.

Bryson YJ, Mirochnick M, Stek A, Mofenson LM, Connor J, Capparelli EV, Watts DH, Huang S, Hughes MD, Kaiser K, Purdue L, Asfaw Y, Keller M, Smith E; PACTG 353 Team. Pharmacokinetics and safety of nelfinavir when used in combination with zidovudine and lamivudine in HIV-infected pregnant women: Pediatric AIDS Clinical Trials Group (PACTG) Protocol 353. HIV Clin Trials, 9:115-25, 2008.

Buchanan JT, Colvin KM, Vicknair MR, Patel SK, Timmer AM, Nizet V.  Strain-associated virulence patterns of Streptococcus iniae in hybrid-striped bass. Vet Microbiol, 131:145-15, 2008.

Burns JC, Best BM, Mejias A, Mahony L, Fixler DE, Jafri HS, Melish ME, Jackson MA, Asmar BI, Lang DJ, Connor JD, Capparelli EV, Keen ML, Mamun K, Keenan GF, Ramilo O.  Infliximab treatment of intravenous immunoglobulin-resistant kawasaki disease. J Pediatr, 153:833-838, 2008.

Capparelli EV.  Pharmacologic, pharmacodynamic and pharmacokinetic considerations with ibuprofen lysine. Journal of Pediatric Pharmacology and Therapeutics, 12:158-170, 2007.

Capparelli EV, Aweeka F, Hitti J, Stek A, Hu C, Burchett SK, Best B, Smith E, Read JS, Watts H, Nachman S, Thorpe EM, Spector SA, Jimenez E, Shearer WT, Foca M, Mirochnick M for the PACTG 1026s and P1022 study teams.  Chronic administration of nevirapine during pregnancy:  impact of pregnancy on pharmacokinetics. HIV Medicine, 9:214-220, 2008.

Capparelli EV, Syed SS. Nitazoxanide for the treatment of Cryptosporidium parvum in HIV-infected children. Pediatr Infect Dis J, Sep 24 2008. [Epub ahead of print].

Carlin AF, Lewis AL, Varki A, Nizet V.  Group B streptococcal capsular sialic acid interacts with Siglecs (immunoglobulin-like lectins) on human leukocytes.

J Bacteriol, 189:1231-1237, 2007.

Chadwick EG, Capparelli EV, Ram Yogev R, Pinto JA, Robbins B, Rodman JH, Chen J, Palumbo P, Serchuck L, Hughes M for the P1030 team.  Pharmacokinetics, safety and efficacy of lopinavir/ritonavir in infants less than six months of age: 24 week results. AIDS, 22:249-255, 2008.

Chadwick EG, Pinto J, Yogev R, Alvero CG, Hughes MD, Palumbo P, Robbins B, Hazra R, Serchuck L, Heckman BE, Purdue L, Browning R, Luzuriaga K, Capparelli EV.  Early initiation of lopinavir/ritonavir-based HAART in infants less than 6 weeks of age: oharmacokinetics and 24 week safety and efficacy. Ped Infect Dis J (in press).

Cogen AL, Nizet V, Gallo RL.  Skin microbiota: A source of disease or defence? Br J Dermatol, 158:442-455, 2008.

Cole JN, Aquilina JA, Hains PG, Henningham A, Sriprakash KS, Caparon MG, Nizet V, Kotb M, Cordwell SJ, Djordjevik SP, Walker MJ.  Role of group A Streptococcus HtrA in the maturation of SpeB protease. Proteomics, 7:4488-4498, 2007.

Dahesh S, Hensler ME, van Sorge NM, Gertz, RE, Schrag S, Nizet V, Beall BW.  Point mutation in the group B streptococcal pbp2x gene conferring decreased susceptibility to b-lactam antibiotics. Antimicrob Agents Chemother, 52:2915-2918, 2008.

Darbari DS, van Schaik RH, Capparelli EV, Rana S, McCarter R, van den Anker J.UGT2B7 promoter variant - 840G>A contributes to the variability in hepatic clearance of morphine in patients with sickle cell disease. Am J Hematol, 83:200-2, 2008.

Dawes S, Suarez P, Casey CY, Cherner M, Marcotte TD, Letendre S, Grant I, Heaton RK; HNRC Group HIV Neurobehavioral Research Center Group (Capparelli EV, Collaborator). Variable patterns of neuropsychological performance in HIV-1 infection. J Clin Exp Neuropsychol, 30:613-26, 2008.

Diaz SM, Rodarte A, Foley J, Capparelli EV. Pharmacokinetics of dexmedetomidine in postsurgical pediatric intensive care unit patients: Preliminary study. Pediatr Crit Care Med, 8:419-424, 2007.

Flynn PM, Rodman J, Lindsey JC, Robbins B, Capparelli EV, Knapp KM, Rodriguez JF, McNamara J, Serchuck L, Heckman B, Martinez J, PACTG P1012 Team. Intracellular pharmacokinetics of once versus twice daily zidovudine and lamivudine in adolescents. Antimicrob Agents Chemother, 51:3516-22, 2007.

Gallo RL, Nizet V. Innate barriers against skin infection and associated disorders. Drug Disc Today Dis Mech, 2008 (published online early).

Gillen CM, Courtney HS, Schulze K, Rohde M, Wilson MR, Timmer AM, Guzman CA, Nizet V, Chhatwal GS, and Walker MJ. Apolipoprotein AI binding and epithelial cell binding by the serum opacity factor protein of Streptococcus pyogenes are functionally discrete. J Biol Chem, 283:6359-6366, 2008.

Goicoechea M, Vidal A, Capparelli E, Rigby A, Kemper C, Diamond C, Witt MD, Haubrich R, California Collaborative Treatment Group (B. Best, collaboratory). A computer-based system to aid in the interpretation of plasma concentrations of antiretrovirals for therapeutic drug monitoring. Antivir Ther, 12:55-62, 2007.

Goicoechea M, Best BM. Efavirenz/emtricitabine/tenofovir disoproxil fumarate fixed-dose combination: first-line therapy for all? Expert Opin Pharmacother, 8:371-82, 2007.

Goicoechea M, Liu S, Best B, Sun S, Jain S, Kemper C, Witt M, Diamond C, Haubrich R, Louie S, CCTG 578 Team. Increased tenofovir-associated renal toxicity in protease inhibitor- versus non-nucleoside reverse transcriptase inhibitor-based therapy. J Infect Dis, 197:102-108, 2008.

Grewal PK, Uchiyama S, Ditto D, Varki N, Le DT, Nizet V, Marth JD.  The Ashwell receptor mitigates the lethal coagulopathy of sepsis. Nat Med, 4:648-655, 2008.

Hensler ME, Quach D, Hsieh CJ, Doran KS, Nizet V. CAMP factor is not essential for systemic virulence of Group B Streptococcus. Microb Pathogen, 44:84-8, 2008.

Hensler ME, Miyamoto S, Nizet V. Group B streptococcal b-hemolysin/cytolysin directly impairs cardiomyocyte viability and function. PLoS One, 3:e2446, 2008.

Hsu LC, Ali R, McGillivray S, Tseng PH, Mariathasan S, Humke E, Eckmann L, Powell J, Nizet V, Dixit V, Karin M. A NOD2-NALP1 complex mediates caspase-1 dependent IL-1b secretion in response to Bacillus anthracis infection and muramyl dipeptide. Proc Natl Acad Sci USA, 105:7803-7808, 2008.

James LP, Capparelli EV, Simpson PM, Letzig L, Roberts D, Hinson JA, Kearns GL, Blumer JL, Sullivan JE and the Network of Pediatric Pharmacology Research Units (NICHD).  Acetaminophen-associated hepatic injury: Evaluation of acetaminophen protein adducts in children and adolescents with acetaminophen overdose. Clin Pharmacol Ther, 84:684-909, 2008.

Kraus D, Herbert S, Kristian S, Nizet V, Götz F, Peschel A. The GraRS regulatory system controls in vivo susceptibility of Staphylococcus aureus to antimicrobial host defenses. BMC Microbiol, 8:85, 2008.

Kristian SA, Timmer AM, Liu GY, Lauth X, Sal-Man N, Rosenfeld Y, Shai Y, Gallo RL, Nizet V. Impairment of innate immune killing mechanisms by bacteriostatic antibiotics. FASEB J, 21:1107-1126, 2007.

Kwinn LA, Khosravi A, Aziz RK, Timmer AM, Doran KS, Kotb M, Nizet V. Genetic characterization and virulence role of the RALP3/LSA locus upstream of the streptolysin S operon in invasive M1T1 group A Streptococcus. J Bacteriol, 189:1322-1329, 2007.

Kwinn LA, Nizet V. How group A Streptococcus circumvents host phagocyte defenses. Future Microbiol, 2 :75-84, 2007.

Lee SW, Mitchell DA, Markley AL, Hensler ME, Gonzalez D, Wohlrab A, Dorrestein PC, Nizet V, Dixon JE.  Discovery of a widely distributed toxin biosynthetic gene cluster. Proc Natl Acad Sci USA, 105:5879-5884, 2008.

Lewis AL, Cao H, Patel SK, Diaz S, Ryan W, Carlin AF, Lewis WG, Varki A, Chen X, Nizet V. NeuA O-acetylesterase activity modulates O-acetylation of capsular sialic acids in group B Streptococcus. J Biol Chem, 282:27562-27571, 2007.

Letendre SL, Marquie-Beck J, Ellis RJ, Woods SP, Best B, Clifford DB, Collier AC, Gelman BB, Marra C, McArthur JC, McCutchan JA, Morgello S, Simpson D, Alexander TJ, Durelle J, Heaton R, Grant I; The CHARTER group. The role of cohort studies in drug development: Clinical evidence of antiviral activity of serotonin reuptake inhibitors and HMG-CoA reductase inhibitors in the central nervous system.J Neuroimmune Pharmacol, 2:120-127, 2007.

Letendre S, Marquie-Beck J, Capparelli EV, Best B, Clifford D, Collier AC, Gelman BB, McArthur JC, McCutchan JA, Morgello S, Simpson D, Grant I, Ellis RJ; CHARTER Group. Validation of the CNS ­penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol, 65:65-70, 2008.

Liu C-I, Liu GY, Song Y, Yin F, Hensler ME, Jeng WY, Nizet V, Wang AH, Oldfield E. A cholesterol biosynthesis inhibitor blocks Staphylococcus aureus virulence. Science, 319: 391-394, 2008. *share senior authorship

Locke JB, Colvin KM, Varki N, Vicknair MR, Nizet V, Buchanan JT. The Streptococcus iniae beta-hemolysin streptolysin S is a virulence factor in fish infection. Dis Aquat Organ, 76:17-26, 2007.

Locke JB, Colvin KM, Datta AK, Patel SK, Naidu NN, Neely MN, Nizet V, Buchanan JT. Streptococcus iniae capsule impairs phagocytic clearance and contributes to virulence in fish. J Bacteriol, 189:1279-1287, 2007.

Locke JB, Aziz RK, Vicknair MR, Nizet V, Buchanan JT. Streptococcus iniae M-like protein contributes to virulence in fish and is a target for live-attenuated vaccine development. PLoS One, 3:e2824, 2008.

McNamara CW, Zinkernagel AS, Macheboeuf P, Cunningham MW, Nizet V, Ghosh P.  Coiled-coil irregularities and instabilities in Group A Streptococcus M1 are required for virulence functions. Science, 319:1405-1408, 2008.

Maisey HC, Hensler MC, Nizet V, Doran KS. Group B streptococcal pili proteins contribute to adherence and invasion of brain microvascular endothelial cells. J Bacteriol, 189:1464-1467, 2007.

Maisey HC, Hensler ME, Quach D, Liu GY, Gallo RL, Nizet V, Doran KS. A group B streptococcal pilus protein promotes phagocyte resistance and systemic virulence. FASEB J, 22:1715-1724, 2008.

Maisey HC, Doran KS, Nizet V.  Recent advances in understanding the molecular basis of group B streptococcal virulence. Exp Rev Mol Med, 10:e27, 2008.

May S, Letendre S, Haubrich R, McCutchan JA, Heaton R, Capparelli EV, Ellis R.  Meeting practical challenges of a trial involving a multitude of treatment regimens:  An example of a multi-center randomized controlled clinical trial in neuroAIDS. J Neuroimmune Pharmacol, 2:97-104, 2007.

Meluzzi D, Zheng W, Hensler M, Nizet V, Dorrestein PC. Top-down mass spectrometry on low-resolution instruments: characterization of phosphopantheteinylated carrier domains in polyketide and non-ribosomal biosynthetic pathways. Bioorg Med Chem Lett, 18:3107-3111, 2008.

Mirochnick M, Best BM, Stek AM, Capparelli EV, Hu C, Burchett SK,  Holland DT,  Smith E, Sreedhar G,  Read JS  for the PACTG 1026s study team.  Lopinavir exposure with an increased dose during pregnancy. JAIDS, 2008 (published online early).

Nizet V. Understanding how leading bacterial pathogens subvert innate immunity to reveal novel therapeutic targets. J Allergy Clin Immunol, 120:13-22, 2007.

Nizet V, Rothenberg ME. Mitochondrial missile defense. Nat Med, 9:910-912, 2008.

Park B, Nizet V, Liu GY.  Role of Staphylococcus aureus catalase in niche competition against Streptococcus pneumoniae. J Bacteriol, 190:2275-2278, 2008.

Peyssonnaux C, Cejudo P, Doedens A, Zinkernagel AS, Johnson RS, Nizet V. Cutting edge:  Essential role of hypoxia inducible factor-1a in development of LPS-induced sepsis. J Immunol, 178:7516-7519, 2007.

Peyssonnaux C, Zinkernagel AS, Schuepbach RA, Rankin E, Vaulont S, Haase VH, Nizet V*, Johnson RS*. Regulation of iron homeostasis by the hypoxia inducible transcription factors (HIF). J Clin Invest 117:1926-1932, 2007. *share senior authorship.

Peyssonnaux C, Nizet V, Johnson R.  Role of the hypoxia-inducible factors iron metabolism. Cell Cycle, 7:28-32, 2008.

Peyssonnaux C, Boutin A, Zinkernagel A, Datta V, Nizet V, Johnson RS. Critical role of HIF-1a in keratinocyte defense against bacterial infection. J Invest Dermatol, 128:1964-1968, 2008.

Rakhmanina NY, Capparelli EV, van den Anker JN, Williams K, Sever JL, Spiegel HM, Soldin SJ. Nevirapine concentration in nonstimulated saliva: an alternative to plasma sampling in children with human immunodeficiency virus infection. Ther Drug Monit, 29:110-7, 2007.

Rakhmanina NY, Capparelli EV, van den Anker JN. Personalized therapeutics:  HIV treatment in adolescents. Clin Pharmacol Ther, 84:734-740, 2008.

Read J, Best B, Stek A, Hu C, Capparelli EV , Holland D, Burchett S, Smith M, Sheeran E, Shearer W, Febo I, Mirochnick M.  Pharmacokinetics of new 625 mg nelfinavir formulation during pregnancy and postpartum. HIV Med,  9:875-882, 2008.

Rius J, Guma M, Schachtrup C, Akassoglou K, Zinkernagel AS, Nizet V, Johnson RS, Haddad GG, Karin M. NF-aB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1a. Nature, 453:807-811, 2008.

Robbins BL, Havens PL, Capparelli EV, Chadwick EG, Yogev R, Serchuck L, Worrell C, Alvero C, Heckman B, Pelton SI, Aldrovandi G, Borokowsky W, Rodman J for the PACTG 1038 Team.  Pharmacokinetics of high-dose lopinavir/ritonavir with and on-nucleoside reverse transcriptase inhibitors in HIV infected pediatric and adolescent patients previously treated with protease inhibitors. Antimicrob Agents Chemother, 52:3276-3283, 2008.

Saitoh A, Sarles E, Capparelli EV, Aweeka F, Kovacs A, Burchett SK, Wiznia A, Nachman S, Fenton T, Spector SA.  CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1 infected children. AIDS, 21:2191-2199, 2007.

Timmer AM, Nizet V. IKKb/NF-bB and the miscreant macrophage. J Exp Med, 205:1255-1259, 2008.

Timmer AM, Timmer JC, Pence MA, Hsu LC, Ghochani M, Frey TG, Karin M, Salvesen GS, Nizet V. Streptolysin O promotes group A Streptococcus immune evasion by accelerated macrophage apoptosis. J Biol Chem, 2008 (published online early).

Tremoulet A, Capparelli VE, Patel P, Acosta E, Luzuriaga K, Bryson Y, Wara D, Zorrilla C, Holland Di and Pediatrics AIDS Clinical Trials Group. Population pharmacokinetics of lamivudine in HIV-exposed or -infected infants. Antimicrobial Agents Chemo, 2007.

Tremoulet AH, Best BM, Song S, Wang S, Corinaldesi E, Eichenfield J , Martin DD, Newburger JW, and Burns JC. Resistance to intravenous immunoglobulin in children with Kawasaki disease. J Peds, 153:117-121, 2008.

Walker MJ, Hollands A, Sanderson-Smith M, Cole JN, Kirk JK, Henningham A McArthur, JD, Dinkla K, Aziz RK, Kansal RG, Simpson AJ, Buchanan JT, Chhatwal GS, Kotb M, Nizet V. DNase-mediated resistance to neutrophil killing provides selection pressure for a genetic and phenotypic switch promoting invasive group A streptococcal infection. Nat Med, 13:981-986, 2007.

Woods SP, Moran LM, Carey CL, Dawson MS, Iudicello JE, Gibson S, Grant I, Atkinson JH; HIV Neurobehavioral Research Center Group (Capparelli EV, Collaborator).  Prospective memory in HIV infection: is “remembering to remember” a unique predictor of self-reported medication management? Arch Clin Neuropsychol, 23(3):257-70, 2008.

Zinkernagel AS, Nizet V. Staphylococcus aureus: A blemish on skin immunity. Cell Host & Microbe, 1:161-162, 2007.

Zinkernagel AS, Johnson RS, Nizet V. Hypoxia inducible factor (HIF) function in innate immunity and infection. J Mol Med, 85:1339-1346, 2007.

Zinkernagel AC, Peyssonnaux C, Johnson RS, Nizet V.  Pharmacological augmentation of HIF-1a with mimosine boosts the bactericidal capacity of phagocytes. J Infect Dis, 197:214-217, 2008.